Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;269(12):6269-6278.
doi: 10.1007/s00415-022-11317-2. Epub 2022 Aug 9.

Cognitive impairment in psoriasis patients: a systematic review of case-control studies

Daniel Pankowski  1   2 , K Wytrychiewicz-Pankowska  3   4 , W Owczarek  5
Affiliations

Cognitive impairment in psoriasis patients: a systematic review of case-control studies

Daniel Pankowski et al. J Neurol. 2022 Dec.

Abstract

Introduction: Cognitive impairment in chronic diseases such as psoriasis is an increasing clinical challenge.

Objective: To assess the frequency and extent of difficulties in cognitive functioning in people with psoriasis compared to healthy people.

Patients and methods: The systematic review was carried out on the 23rd July, 2021 by two trained psychologists resulting in a selection of 11 studies on 971 patients with psoriasis and 10,242 controls.

Results: A review of the studies showed irregularities in many cognitive domains, including working memory processes, executive functions, long-term verbal memory, attention, and the visuospatial domain. Depending on the methods used to assess cognitive dysfunctions and the characteristics of patients in different studies, large differences in the frequency of cognitive impairment in patients with psoriasis were observed, ranging from 0 to 91.9%.

Conclusions: The authors conclude that there is a need for longitudinal studies to identify factors important for the development and persistence of cognitive impairment in psoriatic patients.

Keywords: Cognitive impairment; Psoriasis; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Witold Owczarek has worked as a Consultant or Speaker and participated as Principal Investigator or Subinvestigator in clinical trials sponsored by AbbVie, Alfasigma, Almirall, Bioderma, Bristol-Myers Squibb, Egis, Eli Lilly, Galenica, Galderma, Janssen-Cilag, Leo Pharma, Medac GmbH, Mylan, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz, Teva Pharmaceuticals, UCB Pharma.

Figures

Fig. 1
Fig. 1
Flow diagram of studies identified, excluded and included in the systematic review. CI cognitive impairment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi: 10.1001/jama.2020.4006. - DOI - PubMed
    1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi: 10.1111/jdv.13854. - DOI - PubMed
    1. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):314–321. doi: 10.1016/j.jaut.2009.12.001. - DOI - PubMed
    1. Armstrong AW, Guerin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968–977. doi: 10.1016/j.jaad.2015.02.1095. - DOI - PubMed
    1. Kwan Z, Bong YB, Tan LL, Lim SX, Yong ASW, Ch’ng CC, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–451. doi: 10.1007/s00403-018-1832-x. - DOI - PubMed

Publication types